WS
FATE icon

Wedbush Securities’s Fate Therapeutics FATE Stock Holding History

Wedbush Securities’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-11,500
Closed -$21K – 802
2016
Q1 		$21K Buy
+11,500
New +$23.7K ﹤0.01% 724

Other funds holding FATE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return

Wedbush Securities's FATE Position: Q2 2016 in Review

Wedbush Securities sold out of Fate Therapeutics (FATE) in Q2 2016, closing a stake of 11,500 shares — an estimated $21K sold.

Wedbush Securities first reported a position in FATE in Q1 2016 and held it in 1 quarter. The position peaked at $21K in Q1 2016. 39 funds tracked by Wall St. Rank hold FATE as of Q2 2016.

  • Wedbush Securities reported no remaining Fate Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Wedbush Securities sold 11,500 Fate Therapeutics shares in Q2 2016, an estimated $21K.
  • Wedbush Securities first reported a position in Fate Therapeutics in Q1 2016 and held it in 1 quarter.
  • Wedbush Securities's Fate Therapeutics position peaked at $21K in Q1 2016.
  • 39 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2016.

Based on Wedbush Securities's 13F filing for Q2 2016, filed 2 Aug 2016.